Expression of Tim-3 on Neutrophils in Ankylosing Spondylitis
NCT07383805 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 81
Last updated 2026-02-03
Summary
1. To investigate the expression of Tim-3 on neutrophils in ankylosing spondylitis patients and its correlation with disease activity and inflammatory markers.
2. Association of Tim-3 with sacroiliac MRI findings and the hip inflammatory MRI scoring system (HIMRISS) .
Conditions
- Ankylosing Spondylitis
- AS
- Tim3
Sponsors & Collaborators
-
Assiut University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2026-06-01
- Primary Completion
- 2026-09-01
- Completion
- 2029-09-01
Countries
- Egypt
Study Locations
More Related Trials
-
Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis
NCT05138133 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
The Diagnostic Utility of T Immunoglobulin G and T Immunoglobulin M Biomarkers in Patients With Systemic Lupus Erythematosus Disease : Associations With Disease Activity and Damage
NCT07136337 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.
NCT06916806 ·Status: RECRUITING ·Phase: PHASE1
-
Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus
NCT04293510 ·Status: UNKNOWN
-
Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus
NCT04877691 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Measurement of Anti-dsDNA by Both CLIFT & ELISA
NCT03303508 ·Status: UNKNOWN ·Phase: NA
-
Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)
NCT03878303 ·Status: UNKNOWN ·Phase: PHASE1
-
Association of Serum Interleukin-33 Levels With Clinical Manifestations in Systemic Lupus Erythematosus
NCT07149402 ·Status: NOT_YET_RECRUITING
-
TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis
NCT04218890 ·Status: UNKNOWN
-
A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
NCT07175285 ·Status: RECRUITING
-
Ankylosing Spondylitis and Antiphospholipid Antibodies
NCT02809300 ·Status: UNKNOWN ·Phase: NA
-
A Study of the Effect of XmAb®5871 in Patients With Systemic Lupus Erythematosus
NCT02725515 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
NCT01972568 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Epratuzumab in Systemic Lupus Erythematosus
NCT00111306 ·Status: TERMINATED ·Phase: PHASE3
-
Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients
NCT06287125 ·Status: NOT_YET_RECRUITING
-
Ultrasound-Based Detection Of Subclinical Arthritis Among Patients With Systemic Lupus
NCT05844917 ·Status: UNKNOWN ·Phase: NA
-
Real World Evidence of Anifrolumab in Systemic Lupus Erythematosus: Investigator Initiated, Observational, Multicenter Study Evaluating Effectiveness and Safety of Anifrolumab in Active SLE Patients
NCT07215754 ·Status: RECRUITING
-
Identification of Serum Level of Glutathione Peroxidase 4
NCT06554392 ·Status: NOT_YET_RECRUITING
-
Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus
NCT03179046 ·Status: COMPLETED
-
Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)
NCT00383214 ·Status: TERMINATED ·Phase: PHASE3
-
Self-Acupressure on Pain, Fatigue and Sleep Quality in Systemic Lupus Erythematosus
NCT05453422 ·Status: UNKNOWN ·Phase: NA
-
Role of DcR3 in T Cell Activation in SLE and RA
NCT00275899 ·Status: UNKNOWN
-
Predictors of Bone Mineral Density in Lupus Nephritis Activity
NCT06837558 ·Status: NOT_YET_RECRUITING
-
Evaluation of Galectin-3 in Serum and Saliva of Pemphigus Patients
NCT05992727 ·Status: UNKNOWN
-
A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)
NCT03978520 ·Status: COMPLETED ·Phase: PHASE2